GENPF Stock GENIX PHARMACEUTICALS (GENPF, $0.03) was a top loser this week, declining -16.03%

GET DAILY SIGNALS

Get AI intraday signals

GENPF - GENIX PHARMACEUTICALS CORP.

Loading...

Price: $0.03

Daily change: -$0.005725 (-16.03%)

Daily volume: 2K

Weekly price change: -$0.005725 (-16.03%)

Capitalization: $1.1M

Industry: Pharmaceuticals: Generic

GENIX PHARMACEUTICALS (GENPF, $0.03) was a top weekly loser, falling -1 to $0.03 per share. Of the 216 stocks analyzed in the Pharmaceuticals: Generic Industry throughout the week of November 11/17/2025 - 11/24/2025, 2025, of them () exhibited an Uptrend while of them () were in a Downtrend.

Momentum Indicator for GENPF turns positive, indicating new upward trend

GENPF saw its Momentum Indicator move above the 0 level on December 09, 2025. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator turned positive. In of the 28 cases, the stock moved higher in the following days. The odds of a move higher are at .

Technical Analysis (Indicators)

Bullish Trend Analysis

The 50-day moving average for GENPF moved above the 200-day moving average on December 12, 2025. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Bearish Trend Analysis

The 10-day RSI Indicator for GENPF moved out of overbought territory on November 24, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 12 similar instances where the indicator moved out of overbought territory. In of the 12 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 12 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Moving Average Convergence Divergence Histogram (MACD) for GENPF turned negative on November 20, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 20 similar instances when the indicator turned negative. In of the 20 cases the stock turned lower in the days that followed. This puts the odds of success at .

The Aroon Indicator for GENPF entered a downward trend on December 26, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. GENPF’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (21.577). P/E Ratio (0.000) is within average values for comparable stocks, (74.473). GENPF's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.981). GENPF has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.030). GENPF's P/S Ratio (1111.111) is very high in comparison to the industry average of (64.586).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GENPF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock worse than average.